Target Name: IKZF1
NCBI ID: G10320
Review Report on IKZF1 Target / Biomarker Content of Review Report on IKZF1 Target / Biomarker
IKZF1
Other Name(s): DNA-binding protein Ikaros (isoform Ik-6) | IKAROS family zinc finger 1, transcript variant 7 | DNA-binding protein Ikaros (isoform 1) | Ik-8(del) | IKZF1 variant Ik-8 | DNA-binding protein Ikaros (isoform 7) | LYF1 | IKAROS family zinc finger 1, transcript variant Ik-2 | IKAROS family zinc finger 1, transcript variant Ik-7 | IKAROS family zinc finger 1, transcript variant Ik-7(del) | protein phosphatase 1, regulatory subunit 92 | IKZF1 variant 12 | DNA-binding protein Ikaros (isoform Ik-7) | DNA-binding protein Ikaros (isoform Ik-8(del)) | IKZF1 variant 14 | Ik-6 | IKZF1 variant 2 | IKAROS family zinc finger 1, transcript variant Ik-6 | LyF-1 | IKAROS family zinc finger 1, transcript variant 14 | IKAROS family zinc finger 1, transcript variant 11 | IKAROS family zinc finger 1, transcript variant 15 | DNA-binding protein Ikaros (isoform Ik-7(del)) | DNA-binding protein Ikaros (isoform Ik-8) | DNA-binding protein Ikaros (isoform 6) | IKZF1 variant 7 | Hs.54452 | IK1 | IKAROS family zinc finger 1, transcript variant 1 | DNA-binding protein Ikaros (isoform 11) | IKZF1 variant 1 | ZNFN1A1 | IKZF1 variant Ik-8(del) | IKZF1 variant 15 | Ik-4 | Protein phosphatase 1, regulatory subunit 92 | CLL-associated antigen KW-6 | DNA-binding protein Ikaros (isoform 15) | hIk-1 | IKZF1 variant 8 | Lymphoid transcription factor LyF-1 | DNA-binding protein Ikaros (isoform 9) | IKZF1 variant 4 | IKZF1 variant 9 | DNA-binding protein Ikaros (isoform 12) | Ikaros family zinc finger protein 1 | Zinc Finger Protein Subfamily 1A 1 (Ikaros) | IKZF1 variant 5 | ikaros family zinc finger protein 1 | zinc finger protein, subfamily 1A, 1 (Ikaros) | IKZF1_HUMAN | IKAROS family zinc finger 1, transcript variant 8 | Ik-7 | IKAROS | lymphoid transcription factor LyF-1 | Ikaros (zinc finger protein) | IKAROS family zinc finger 1, transcript variant 9 | DNA-binding protein Ikaros | IKZF1 variant Ik-7(del) | IKZF1 variant Ik-4 | IKAROS family zinc finger 1, transcript variant 12 | DNA-binding protein Ikaros (isoform 8) | IKAROS family zinc finger 1, transcript variant 4 | DNA-binding protein Ikaros (isoform 13) | IKAROS family zinc finger 1 (Ikaros) | PPP1R92 | IKAROS family zinc finger 1, transcript variant 6 | DNA-binding protein Ikaros (isoform 3) | IKAROS family zinc finger 1, transcript variant 2 | IKZF1 variant Ik-7 | DNA-binding protein Ikaros (isoform 2) | Zinc finger protein, subfamily 1A, 1 (Ikaros) | IKAROS family zinc finger 1, transcript variant 13 | IKZF1 variant 6 | hs.54452 | Ik-8 | DNA-binding protein Ikaros (isoform 5) | IKAROS family zinc finger 1, transcript variant Ik-8(del) | DNA-binding protein Ikaros (isoform 4) | IKZF1 variant 11 | IKZF1 variant Ik-6 | CVID13 | Ik-1 | PRO0758 | IKAROS family zinc finger 1, transcript variant Ik-4 | IKAROS family zinc finger 1, transcript variant Ik-8 | Ikaros | IKZF1 variant Ik-2 | IKAROS family zinc finger 1, transcript variant 5 | IKAROS family zinc finger 1 | IKZF1 variant 13

IKZF1: A Potential Drug Target and Biomarker

Introduction

The Ikazokin family of proteins, known as DNA-binding proteins, plays a crucial role in various cellular processes, including DNA replication, repair, and transcription. One of the proteins in this family is IKAROS (ISOFORM IK-6), a protein that has been shown to interact with DNA and has been identified as a potential drug target and biomarker. In this article, we will explore the structure and function of IKAROS, and discuss its potential as a drug target and biomarker.

Structure and Function

IKAROS is a 21 kDa protein that is expressed in various tissues and organs, including brain, heart, and liver. It is composed of a unique domain that consists of a long amino acid sequence known as the N-terminal hypervariable region (HVR1), a middle domain composed of 116 amino acids known as the catalytic domain, and a C-terminal domain consisting of 31 amino acids known as the C-terminal hypervariable region (HVR2).

The N-terminal HVR1 region of IKAROS is unique and is composed of a specific sequence known as the N-terminal alpha-helix, which is a type of secondary structure that can interact with DNA. The middle domain of IKAROS, known as the catalytic domain, contains a series of conserved amino acids that are involved in protein-protein interactions and may be involved in the protein's activity. The C-terminal HVR2 region is also unique and contains a specific sequence that is known as the C-terminal GXXG repeat , which has been shown to interact with DNA and may be involved in the protein's function.

Expression and Function

IKAROS has been shown to play a role in various cellular processes, including DNA replication, repair, and transcription. In addition, IKAROS has been shown to interact with DNA and has been identified as a potential drug target and biomarker.

IKAROS has been shown to interact with DNA using its N-terminal HVR1 region. IKAROS has been shown to form a complex with DNA in cell culture, where the N-terminal HVR1 region interacts with the GXXG repeat in the C-terminal HVR2 region. This interaction between IKAROS and DNA has been shown to enhance the transcriptional activity of IKAROS in cell culture.

In addition to its interaction with DNA, IKAROS has also been shown to play a role in protein-protein interactions. IKAROS has been shown to interact with several other proteins, including the protein p21 (T-cell factor-inducible gene 1), which is involved in cell growth and survival, and the protein p53 (DNA damage-repair complex protein), which is involved in DNA repair.

Mutations in IKAROS have been shown to have a detrimental effect on various cellular processes, including DNA replication and repair. For example, a missense mutation in the IKAROS gene has been shown to lead to decreased DNA replication and an increased risk of DNA damage in cell culture. In addition, IKAROS has also been shown to play a role in the regulation of cellular processes, including cell growth, apoptosis, and inflammation.

Potential Therapeutic Applications

The therapeutic potential applications of IKAROS as a drug target and biomarker are vast. One of the main potential therapeutic applications of IKAROS is as a treatment for various diseases, including cancer. IKAROS has been shown to play a role in the regulation of cell

Protein Name: IKAROS Family Zinc Finger 1

Functions: Transcription regulator of hematopoietic cell differentiation (PubMed:17934067). Binds gamma-satellite DNA (PubMed:17135265, PubMed:19141594). Plays a role in the development of lymphocytes, B- and T-cells. Binds and activates the enhancer (delta-A element) of the CD3-delta gene. Repressor of the TDT (fikzfterminal deoxynucleotidyltransferase) gene during thymocyte differentiation. Regulates transcription through association with both HDAC-dependent and HDAC-independent complexes. Targets the 2 chromatin-remodeling complexes, NuRD and BAF (SWI/SNF), in a single complex (PYR complex), to the beta-globin locus in adult erythrocytes. Increases normal apoptosis in adult erythroid cells. Confers early temporal competence to retinal progenitor cells (RPCs) (By similarity). Function is isoform-specific and is modulated by dominant-negative inactive isoforms (PubMed:17135265, PubMed:17934067)

The "IKZF1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IKZF1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

IKZF2 | IKZF3 | IKZF4 | IKZF5 | IL-1 Receptor | IL-10 Receptor | IL-11 receptor | IL-12 receptor | IL-13 receptor | IL-15 receptor | IL-17 Receptor | IL-2 receptor | IL-20 receptor | IL-22 Receptor | IL-23 receptor complex | IL-27 receptor | IL-3 receptor | IL-31 Receptor | IL-4 receptor | IL-5 receptor | IL-6 receptor | IL10 | IL10RA | IL10RB | IL10RB-DT | IL11 | IL11RA | IL12A | IL12A-AS1 | IL12B | IL12RB1 | IL12RB2 | IL13 | IL13RA1 | IL13RA2 | IL15 | IL15RA | IL16 | IL17A | IL17B | IL17C | IL17D | IL17F | IL17RA | IL17RB | IL17RC | IL17RD | IL17RE | IL17REL | IL18 | IL18BP | IL18R1 | IL18RAP | IL19 | IL1A | IL1B | IL1F10 | IL1R1 | IL1R2 | IL1RAP | IL1RAPL1 | IL1RAPL2 | IL1RL1 | IL1RL2 | IL1RN | IL2 | IL20 | IL20RA | IL20RB | IL21 | IL21-AS1 | IL21R | IL21R-AS1 | IL22 | IL22RA1 | IL22RA2 | IL23A | IL23R | IL24 | IL25 | IL26 | IL27 | IL27RA | IL2RA | IL2RB | IL2RG | IL3 | IL31 | IL31RA | IL32 | IL33 | IL34 | IL36A | IL36B | IL36G | IL36RN | IL37 | IL3RA | IL4 | IL4I1